On or around 12/13/2016 (Notice of voluntarily dismissal)
Filing Date: December 06, 2016
According to a law firm press release, on August 29, 2016, the two parties announced the signing of a definitive merger agreement pursuant to which Leap Therapeutics, Inc. will acquire Macrocure Ltd. in a merger in a deal. As a result of the merger, Macrocure shareholders are anticipated to receive newly issued shares of Leap common stock.
The complaint alleges that the company: (1) failed to conduct a fair sales process, (2) failed to disclose how much this proposed transaction undervalues the company, and (3) failed to disclose all material information regarding the sale of the company.
This case was voluntarily dismissed on December 13, 2016.
Company & Securities Information
Defendant: Macrocure Ltd.
Industry: Biotechnology & Drugs
Ticker Symbol: MCUR
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Helene Lax, et al. v. Macrocure Ltd., et al.
COURT: S.D. New York
DOCKET #: 16-CV-09438
JUDGE: Hon. George B. Daniels
DATE FILED: 12/06/2016
CLASS PERIOD START: 08/29/2016
CLASS PERIOD END: 12/06/2016
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Monteverde & Associates PC 350 Fifth Avenue, 59th Floor, Monteverde & Associates PC, NY 10118 (212) 971-1341 ·